Acquisition of cgmp-grade GS-441524 for the treatment of covid-19
Ended Purchase Order Awarded Last action
- Contract number
- 75N95022P00137
- Awardee
-
Avista Pharma Solutions, Inc. UEI GRKKCA8LJNE4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $581,604
Award facts
- Opportunity
-
- Acquisition of cGMP-grade GS-441524 for the Treatment of COVID-19 Solicitation · 75N95022Q00102 · Posted Feb 1, 2022
- Contract value 100% obligated
- $581,604.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27713, USA
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $40,250 | |
| Supplemental Agreement for work within scope | $22,918 | |
| Original award | $518,436 |
About this award
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $581,604 firm fixed price purchase order to Avista Pharma Solutions, Inc., doing business as Cambrex, to acquire approximately 2-3 kilograms of cGMP-grade GS-441524 for potential treatment of COVID-19. The award is pursuant to a combined synopsis/solicitation seeking this same cGMP material from Avista, as they are currently producing non-cGMP GS-441524 under Contract No. 75N95021P00063, to ensure material source consistency. Delivery of the cGMP drug substance is required within 18 weeks to Avista's location in Durham, North Carolina. No set-aside designation was used.
Quick answers
Who was awarded contract 75N95022P00137?
75N95022P00137 was awarded to Avista Pharma Solutions, Inc. by National Institute on Drug Abuse (National Institutes of Health) on February 18, 2022.
How much is contract 75N95022P00137 worth?
The government has obligated $581,604 on 75N95022P00137.
Which agency awarded contract 75N95022P00137?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022P00137, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95022P00137 competed?
The extent of competition for 75N95022P00137 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award